Polydeoxyribonucleotide (PDRN) absorbance measurement is the core analytical technique used to quantify DNA content, verify identity, and assess purity in pharmaceutical-grade and cosmetic-grade PDRN materials. This technical article explains the principles of UV spectrophotometric determination at 260 nm, standard test procedures, acceptance criteria for purity ratios, and practical applications in quality control. Whether you are developing salmon-DNA-derived PDRN sodium for injection or cosmetic formulations, understanding absorbance testing is essential for regulatory compliance and batch consistency.
Technical Overview
Polydeoxyribonucleotide (PDRN) is a linear chain polymer composed of deoxyribonucleotide monomers, typically obtained through controlled depolymerization and purification of DNA derived from salmon milt or other fish sources. With a molecular weight distribution generally falling within the 50 to 2,000 kDa range depending on the manufacturing process, PDRN is widely used in regenerative medicine, wound healing products, medical aesthetics, and functional cosmetics.
Because the purine and pyrimidine bases of DNA absorb ultraviolet light strongly at a wavelength of approximately 260 nm, UV spectrophotometry provides the fastest and most reliable means of identifying and quantifying PDRN. The measurement follows the Beer-Lambert law, in which absorbance (A) is directly proportional to the molar concentration (c), the molar extinction coefficient (ε), and the optical path length (l). For double-stranded DNA, an absorbance of 1.0 at 260 nm corresponds to approximately 50 μg/mL, which forms the basis of routine content calculation.
Absorbance determination serves three purposes in PDRN quality control: identity confirmation through spectral scanning, quantitative assay of DNA content, and purity assessment through ratio analysis at multiple wavelengths. These measurements are typically performed by accredited third-party laboratories or in-house quality control facilities operating in compliance with ISO/IEC 17025.
Testing Samples
Pharmaceutical-Grade PDRN Sodium Bulk Substance
Lyophilized powders or sterile bulk active pharmaceutical ingredients intended for injectable PDRN sodium products. These samples require the highest level of analytical rigor, as absorbance data directly support assay values in regulatory submission dossiers.
Cosmetic-Grade PDRN Raw Materials
PDRN concentrates, powders, and premixes supplied to cosmetic manufacturers for use in serums, ampoules, creams, and skin-booster formulations. Absorbance testing verifies declared DNA content and screens for degradation or contamination.
Process Intermediates
DNA hydrolysates, depolymerization reaction mixtures, and chromatographic purification fractions collected during manufacturing. Rapid absorbance checks guide process control and confirm complete removal of proteins, phenols, and other UV-absorbing impurities.
Finished Products and Formulations
Injectable solutions, mesotherapy preparations, and finished cosmetic products containing PDRN as the active or functional ingredient. Formulated samples may require matrix-matched blank correction to account for excipient absorption.
Reference and Stability Samples
Retained batches and stability study samples stored under accelerated and long-term conditions, where absorbance trending helps monitor molecular integrity over the product shelf life.
Testing Items
A comprehensive absorbance determination package for PDRN typically includes the following measurable parameters:
- Ultraviolet absorbance at 260 nm (A260), the primary quantitative measurement for nucleic acid content
- Purity ratio A260/A280, used to detect protein, peptide, and phenolic contamination; pure DNA typically yields a ratio of approximately 1.8 to 2.0
- Purity ratio A260/A230, used to detect residual organic solvents, chaotropic salts, and carbohydrates; acceptable values generally fall between 2.0 and 2.3
- Background absorbance at 320 nm, which reveals turbidity, particulate matter, and light-scattering interference that must be subtracted from the measured values
- Full-wavelength spectrum scanning across 220 to 320 nm to confirm the characteristic nucleic acid spectral profile with a maximum near 260 nm and a minimum near 230 nm
- Specific absorbance (absorption coefficient, E1%1cm) calculated for batch-to-batch consistency evaluation
- Calculated DNA concentration or PDRN content expressed in mg/mL, mg/vial, or percentage of label claim
Testing Methods
Instrumentation and Reference Standards
The determination is performed on a calibrated UV-visible spectrophotometer operated in accordance with recognized practice standards such as GB/T 9721 for chemical reagent UV measurement, ASTM E275 for describing spectrophotometer performance, and the ultraviolet spectrophotometry general chapter of the applicable pharmacopoeia. Matched quartz cuvettes with a 10 mm path length are used for conventional measurements, while microvolume instruments may be employed for limited-quantity samples after appropriate validation.
Sample Preparation
- Dissolve or dilute the PDRN sample in nuclease-free water, physiological saline, or a defined neutral buffer such as phosphate-buffered saline at pH 7.4
- Prepare serial dilutions so that the absorbance at 260 nm falls within the linear working range of 0.1 to 1.0 absorbance units
- Prepare a matching blank solution containing all formulation excipients when testing finished products
- Ensure complete dissolution, and clarify turbid solutions by centrifugation or filtration through low-DNA-binding membranes where appropriate
Measurement Procedure
- Zero the instrument against the blank solution and verify baseline flatness across the scan range
- Measure absorbance at 260 nm, 280 nm, 230 nm, and 320 nm in duplicate or triplicate
- Apply turbidity correction by subtracting the A320 value from the A260 reading when scattering is detected
- Calculate DNA concentration using the relationship: concentration (μg/mL) = A260 × dilution factor × 50 (for double-stranded DNA)
- Calculate the ratios A260/A280 and A260/A230 and compare them against established acceptance criteria
- Record the full absorption spectrum from 220 to 320 nm to verify the characteristic shape of nucleic acid absorbance
Method Validation Parameters
For quantitative release testing, the absorbance method should be validated for linearity, range, accuracy, precision (repeatability and intermediate precision), specificity against formulation matrix interference, and robustness in line with ICH Q2 analytical validation principles. System suitability checks, including wavelength accuracy verification using holmium oxide filters and photometric accuracy verification using potassium dichromate solution, are performed before each analytical sequence.
Applications
- Quality control release testing of PDRN sodium active substances for injectable and topical pharmaceutical products
- Verification of declared PDRN content in cosmetic raw materials and finished formulations during incoming inspection
- Supporting documentation for regulatory submissions, including cosmetic product notification files and drug registration dossiers
- Manufacturing process optimization, including monitoring of depolymerization yield and purification efficiency
- Long-term and accelerated stability studies tracking spectral integrity and content retention over the product shelf life
- Research and development applications in tissue regeneration, wound healing, and anti-aging studies where accurate nucleic acid dosing is required
- Batch-to-batch comparability assessment and supplier qualification programs
FAQ
Why is 260 nm used as the measurement wavelength for PDRN?
The conjugated double-bond systems of the purine and adenine-containing nucleobases in DNA exhibit maximal ultraviolet absorption at approximately 260 nm. This wavelength therefore offers the highest sensitivity for nucleic acid quantification and is the internationally recognized reference point for DNA-based measurements.
What does a low A260/A280 ratio indicate?
A ratio below approximately 1.8 typically indicates contamination with proteins, peptides, or phenolic compounds that absorb near 280 nm. In PDRN manufacturing, a low ratio signals incomplete purification and usually triggers further investigation or rejection of the batch.
Can absorbance testing be performed directly on finished cosmetic formulations?
Yes, provided that a matrix-matched blank is prepared containing all excipients except the PDRN. Excipients that strongly absorb in the 230 to 280 nm region can interfere with ratio measurements, and in such cases supplementary methods such as fluorescent dye binding assays may be recommended for confirmation.
How is PDRN content calculated from the absorbance reading?
For double-stranded DNA, the concentration in μg/mL equals the corrected A260 value multiplied by the dilution factor and by 50, assuming a 10 mm path length. The result is then converted into the reporting units required by the product specification, such as milligrams per vial or percentage of label claim.
What are typical acceptance criteria for pharmaceutical-grade PDRN?
While specifications are product-specific, common criteria include an A260/A280 ratio within 1.8 to 2.0, an A260/A230 ratio within 2.0 to 2.3, a characteristic spectrum shape, and assay content within 90 to 110 percent of the declared amount. Accredited third-party laboratories can tailor these limits to individual regulatory requirements.